DT02 Rec'd PCT/PT0

1 8 JAN 2005 PTO-1390 (Rev. 12-20)

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER 701826-056360

S. APPINCATION NOT IT known, age 37 CFR 1.5)

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/CA2003/001069 16 July 2003 (16.07.2003) 16 July 2002 (16.07.2002) TITLE OF INVENTION COMPOSITION FOR CYTOCOMPATIBLE, INJECTABLE, SELF-GELLING CHITOSAN SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS OR BIOLOGICALLY ACTIVE FACTORS APPLICANT(S) FOR DO/EO/US BIO SYNTECH CANADA, INC.; HOEMANN, Caroline; CHENITE, Abdellatif; BUSCHMANN, Michael; SERREQI, Alessio and SUN, Jun Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). \mathbf{X} A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). Other items or information: Cover Sheet (WO 2004/006961 A1); Notice Informing the Applicant of Communication of Imernational Application to Designated Offices (PCT/IB/308); Notifice Other items or information: Change (1st inventor Hoemann) (PCT/IB/306); Int. Search Report (PCT/IB/202); Express Mail Cen. EL 948121855 US; Check - \$1.015.00; Return Rec. Postcard. pplication to Designated Offices (PCT/IB/308); Notification of Recording of

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

DT39 Rec'd PCT/PTO

DT29 Rec'd PCT/PTO 18 JAN 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NOW KNOWN, 2017 CFR 1.5)			INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER			
	-0/2/21	564	PCT/CA2003/0	01069	701826-0	56360		
21. The following fees are submitted:					Applicant use	Office use only		
X a) Basic national fee				\$300.00	\$ 300.00			
X b) Examination fee\$200.00			\$ 200.00					
X c) Search fee\$500.00					\$ 500.00			
	TOTAL OF ABOVE CA	\$ 1,000.00	,					
	ee for specification and d							
	mputer program listing fil 0 sheets of paper or frac							
Total Sheets Extra sheets		Number of each additional 50 or fraction RATE						
		thereof (round up to a whole number)						
34 - 100 =	-66 /50 =			× \$250.00	\$ 0.00			
	30.00 for furnishing the ordate (37 CFR 1.492(e)).	\$ 130.00						
CLAIMS	NUMBER FIL	ED .	NUMBER EXTRA	RATE	\$	<u> </u>		
Total claims	34	- 20 =	14	x \$50.00	\$ 700.00			
Independent clai	ims 4	- 3 =	1	x \$200.00	\$ 200.00			
MULTIPLE DEP	ENDENT CLAIM(S) (if ap	+ \$360.00	\$ 0.00					
		\$ 2,030.00						
X Applicant of by ½	laims small entity status.	\$ 1,015.00						
		\$ 1,015.00						
	of \$130.00 for furnishing the date (37 CFR 1.492(f)).	\$ 0.00						
		\$ 1,015.00						
	g the enclosed assignmer e cover sheet (37 CFR 3.	\$ 0.00						
		\$ 1,015.00						
			\$					
			\$					
a. X A chec	k in the amount of \$	es is enclosed.						
a. IX A check in the amount of \$ to cover the above fees is enclosed. b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.								
A duplicate copy of this sheet is enclosed.								
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No50-0850 A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:								
David S. Resnick					m			
NIXON PEABODY LLP SIGNATURE								
100 Summer Street David S. Re					esnick			
Boston, MA 02110-2131 NAME								
US	•			34,235	ON NUMBER			
				REGISTRATIO	ON NOWREK			

Practitioner's Docket No. 701826-056360

PATENT

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/CA2003/001069	16 July 2003	16 July 2002
	16.07.03	16.07.02

TITLE OF INVENTION:

COMPOSITION FOR CYTOCOMPATIBLE,

INJECTABLE, SELF-GELLING CHITOSAN SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS

OR BIOLOGICALLY ACTIVE FACTORS

APPLICANT FOR DO/US:

BIO SYNTECH CANADA, INC.; HOEMANN, Caroline; CHENITE, Abdellatif; BUSCHMAN, Michael; SERREQI,

Alessio; and SUN, Jun

INVENTORS FOR DO/US:

HOEMANN, Caroline; CHENITE, Abdellatif; BUSCHMAN,

Michael; SERREQI, Alessio; and SUN, Jun

U.S. SERIAL NO.:

TO BE ASSIGNED

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. <u>EL 948 121 855 US</u> in an envelope addressed to MAIL STOP PCT, Commissioner of Patents, Box 1450, Alexandria,

VA 22313-1450 .

Date: 1/18/05

)5 Mode M. Aguirre

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE (INTERNATIONAL APPLICATION (37 C.F.R. § 1.10(c))

I declare that, on January 18, 2005, I deposited with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number <u>EL 948 121 855 US</u>, addressed to "MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450," and having an express mail certification that I executed, the following papers:

- 1. Transmittal Letter Form PTO-1390 in Duplicate (4 pp.);
- 2. Preliminary Amendment (7 pp.);
- 3. Application Data Sheet (9 pp.);
- 4. Cover Sheet (WO 2004/006961 A1) (1 pp.);
- 5. Notice Informing the Applicant of the Communication of the International Application to the Designated Offices (PCT/IB/308) (1 pg.);
- 6. Notice of the Recording of a Change 1st Inventor Hoemann (PCT/IB/306) (1 pg.);
- 7. International Search Report (PCT/IB/220) (4 pp.);
- 8. Check \$1,015.00;

9. Return Receipt Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Date January 18, 2005

icole M. Aguirre